|
Matrix metalloproteinases and Diabetic Nephropathy Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Matrix metalloproteinases and Diabetic Nephropathy conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Matrix metalloproteinases and Diabetic Nephropathy Clinical research trials and Matrix metalloproteinases and Diabetic Nephropathy healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Matrix metalloproteinases and Diabetic Nephropathy. Matrix metalloproteinases and Diabetic Nephropathy Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Matrix metalloproteinases and Diabetic Nephropathy clinical trial. Subjects frequently obtain the most expert healthcare possible for their Matrix metalloproteinases and Diabetic Nephropathy condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Matrix metalloproteinases and Diabetic Nephropathy  Matrix metalloproteinases and Diabetic Nephropathy
Matrix metalloproteinases and Diabetic Nephropathy
For Condition: Diabetic Nephropathy,Diabetes Mellitus, Type 1
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs. Abnormal activity of these enzymes has been implicated in many disease processes including rheumatoid arthritis, dental disease and metastatic cancer. Recent studies also suggest that elevations in blood sugar may abnormally effect MMP enzyme activity. Decreased activity of some of these MMP enzymes may be a partial cause of the abnormal enlargement of the kidney (renal hypertrophy) seen at the start of diabetic kidney disease (nephropathy). Preliminary clinical data from our laboratory confirm that children with newly diagnosed type 1 diabetes mellitus (DM) have lower blood levels of some of these enzymes at the time of very high blood sugar readings. However, these enzyme levels become normal again as blood sugar levels improve with insulin treatment. In the present study, we propose to investigate the hypothesis that MMPs are involved in the cause of diabetic kidney disease by measuring concentrations of specific MMPs and some related proteins in the blood and urine of patients with type 1 DM who are between the ages of 14-40 years. We will enroll some patients who are recently diagnosed with diabetes, some who have had diabetes for several years, but without signs of kidney disease, and some with long-term diabetes and various degrees of kidney disease. Continuous Subcutaneous Glucose Monitoring, conducted for 3-4 days, will also be provided as a part of this study, to determine how different levels of blood sugar control might relate to different levels of MMP enzyme activity in the blood. We anticipate that this study will help to establish a link between abnormal MMP activity and the cause of nephropathy in type 1 DM, allowing scientists to design better therapies for the prevention and treatment of diabetes-related kidney problems.
Details:
Eligibility:
Study Type: Observational, Screening, Cross-Sectional, Defined Population, Prospective Study
Minimum Age/Maximum Age: 14 Years/40 Years
Genders: Both
Protocol Entry Criteria: Type 1 Diabetes with or without kidney disease and past puberty.
Total Enrollment: 330
Location and Contact Information:
Arkansas Children's Hospital/University of Arkansas for Medical Sciences *Recruiting*
Little Rock, Arkansas, 72202
United States
Recruiting Cynthia Moreau 501-364-1975
Additional Information:
Study ID Numbers: MMADN;
Study Start Date: March 2003
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067886
Other Diabetes Mellitus, Type 1 Studies:
1. The effect of LY333531 on protein in the urine in patients with type 2 diabetes.
2. Matrix metalloproteinases and Diabetic Nephropathy
3. Pirfenidone: A New Drug to Treat Kidney Disease in Patients with Diabetes
4. Study of Drugs for High Blood Pressure and High Cholesterol in American Indians with Type 2 Diabetes at High Risk of Kidney or Heart Disease
5. Treatment of Diabetic Nephropathy
Related Studies:
Other Diabetes Mellitus, Type 1 Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
Matrix metalloproteinases and Diabetic Nephropathy
|
|
|
|
|
|
|
|
